Satellos Bioscience Inc. (TSE:MSCL) has released an update.
Satellos Bioscience Inc., a biotech firm focusing on innovative treatments for muscle diseases, will be featured in upcoming virtual investor conferences with CEO Frank Gleeson presenting at Stifel 2024 CNS Days in March and the Cantor Muscular Dystrophy Symposium in April. These presentations will be accessible via live webcast on the company’s website, with replays available post-event. Satellos, known for its pioneering MyoReGenX platform, is advancing a potential disease-modifying drug for Duchenne muscular dystrophy.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
